NEWCervoMed Reports Third Quarter 2026 Financial Results and Provides Pipeline and Clinical Updates
8-K
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
8-K
CervoMed Inc. Makes Investor Presentation Available on Website
8-K
CervoMed Presents Initial Phase 2a Trial Results of Neflamapimod in nfvPPA Demonstrating Reductions in Neurodegeneration Biomarker
8-K
CervoMed Inc. Makes Corporate and Clinical Presentation Materials Available on Website
8-K
CervoMed Announces New Neflamapimod 50 mg Tablet Formulation, FDA Removal of Drug Exposure Limit, and Plans for 100 mg BID Regimen
